GLP-1 side effects most often affect digestion: nausea, diarrhea, vomiting, constipation and stomach pain are the most common.
Severe stomach pain, vomiting that stops you keeping fluids down, or signs of pancreatitis or gallbladder problems need prompt medical review.
This guide explains the common digestive effects, the thyroid, pancreas and gallbladder warnings, hydration and kidney concerns, the 2026 FDA safety update and how side effects are reviewed before treatment.
| Risk bucket | Examples described in current labels | Appropriate response frame |
|---|---|---|
| Common digestive effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion | Track timing, severity, intake and hydration; discuss persistent symptoms |
| Volume depletion | Ongoing vomiting or diarrhea with reduced fluids | Contact the clinical team; kidney risk may need assessment |
| Gallbladder or pancreatic concern | Persistent severe abdominal pain, sometimes with vomiting | Seek prompt medical evaluation rather than self-diagnosing |
| Low blood glucose | Greater concern with insulin or an insulin secretagogue | Review the complete diabetes regimen and recognize symptoms |
| Severe allergy | Swelling, breathing difficulty or a serious hypersensitivity reaction | Obtain urgent medical help |
| Procedure-related aspiration risk | Delayed stomach emptying before anesthesia or deep sedation | Tell the procedure and anesthesia teams about the medicine |
In this article
How Can You Make GLP-1 Side Effects Easier?
Most digestive side effects are worst when starting or after a dose increase, which is why products are started low and raised step by step. Following that schedule, rather than rushing ahead, is one of the simplest ways to feel better.
Eating smaller meals, stopping when you feel full, going easy on greasy or fried food and drinking enough fluids help many people. Symptoms that do not settle, or that stop you eating and drinking, should go to your prescriber.
Nausea, constipation and other digestive effects
Why do digestive effects happen?
GLP-1 receptor agonists influence appetite, glucose-dependent insulin release and the movement of food through the stomach. Zepbound® (tirzepatide) acts at both GIP and GLP-1 receptors. These effects help explain why nausea, fullness, belching, abdominal discomfort, diarrhea or constipation can occur.
Symptoms often appear during treatment initiation or after a change in exposure, but their timing and intensity vary. A person should not alter a prescription by following a general article. The prescribing clinician can interpret symptoms in relation to the specific product, other medicines, hydration and health history. The GLP-1 medication explainer covers mechanism and how the approved products differ.
Vomiting and diarrhea matter beyond discomfort because fluid loss can lead to dehydration. FDA labels warn about acute kidney injury due to volume depletion, especially when gastrointestinal reactions are substantial. Reduced intake can also complicate nutrition and the management of other conditions.
Which effects are listed most often?
The current Wegovy® (semaglutide) label lists these among the most common adverse reactions:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
It also lists indigestion, abdominal distension, belching, reflux, headache, fatigue, dizziness and other effects. The Zepbound label has a similar digestive emphasis but is not identical.
Trial tables compare side-effect rates with a control group. They describe patterns, not whether your next symptom will occur or what caused it.
Some weight-management labels list hair loss. Weight change, nutrition and illness can also cause shedding. Report when it began and which areas are affected.
Injection-site reactions can occur with injectable formulations. Oral and injectable forms also have different administration and interaction details. Dosing and step-up schedules belong to the current prescription and the prescribing physician.
Thyroid warnings, pancreatitis and gallbladder risks
What does the thyroid boxed warning mean?
Wegovy and Zepbound weight-management labels carry a boxed warning about thyroid C-cell tumors. The medicines caused these tumors in rodents. The labels state that it is unknown whether they cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
The products are contraindicated in people with a personal or family history of medullary thyroid carcinoma and in people with Multiple Endocrine Neoplasia syndrome type 2. That history should be reviewed before prescribing. A neck mass, persistent hoarseness, trouble swallowing or breathing difficulty warrants clinical attention, but those symptoms can have other causes.
The warning should be stated accurately. Describing a confirmed human cancer risk would go beyond the label; omitting the boxed warning would minimize a material safety fact.
| Label point | Wegovy® | Zepbound® |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Receptor targets | GLP-1 | GIP and GLP-1 |
| Boxed warning | Thyroid C-cell tumors in rodents | Thyroid C-cell tumors in rats |
| Contraindicated with MTC or MEN 2 history | Yes | Yes |
| Most common reactions | Nausea, diarrhea, vomiting, constipation, abdominal pain | Nausea, diarrhea, vomiting, constipation, abdominal pain |
How are pancreatitis and gallbladder problems described?
Acute pancreatitis has been observed with GLP-1 receptor agonists, and product labels instruct clinicians to act if it is suspected. Severe, persistent abdominal pain that may radiate to the back, with or without vomiting, needs prompt medical assessment. An article cannot determine whether that pain is pancreatic, gallbladder, gastrointestinal or something else.
Gallstones and gallbladder inflammation also appear in warnings and clinical-trial data. Substantial weight loss itself can increase gallstone risk, which makes the relationship more complex than a simple symptom list. Right-upper abdominal pain, fever or yellowing of the skin or eyes should not be managed only through online advice.
These events are different from brief mild nausea. Grouping all abdominal symptoms together can either alarm people unnecessarily or cause a serious pattern to be overlooked.
When can low blood glucose occur?
GLP-1 therapies have glucose-dependent effects, but hypoglycemia risk rises when they are used with insulin or medicines that increase insulin release, such as sulfonylureas. Current labels tell clinicians to consider that combined regimen and educate patients about low-glucose symptoms.
Shakiness, sweating, confusion, hunger, weakness or a fast heartbeat can occur with hypoglycemia, although symptoms vary. Someone treated for diabetes should follow the monitoring and response plan provided by the clinical team. A weight-management article should not supply a replacement medication adjustment.
The complete medicine list matters. So do kidney function, eating patterns and changes in intake. A prescriber may need coordination with the clinician managing diabetes rather than treating each prescription in isolation.
Dehydration, kidney health and anesthesia
Why do kidney health and hydration matter?
The kidney warning is often connected to fluid loss from gastrointestinal reactions. Persistent vomiting or diarrhea, inability to maintain fluid intake or signs of dehydration can require evaluation. People with existing kidney impairment may have less margin for a change in volume status.
This does not mean that ordinary thirst proves kidney injury. It means symptom duration, severity, urine output, other medicines and baseline kidney health belong in the clinical conversation. Laboratory testing may be appropriate when the history raises concern.
What should be disclosed before surgery or sedation?
GLP-1 therapies can delay gastric emptying. FDA labels describe rare reports of pulmonary aspiration during general anesthesia or deep sedation even when patients reported following pre-procedure fasting instructions. The procedure team needs to know about current use before planning anesthesia.
Patients should follow instructions from the prescribing, procedural and anesthesia teams rather than a universal stop-date found online. The decision depends on the medicine, procedure, symptoms and current professional guidance. Never conceal use because a procedure is already scheduled.
Delayed gastric emptying can also affect the absorption of oral medicines. The practical importance varies by product and by the oral drug, so the clinician or pharmacist should review medications with a narrow therapeutic margin or other timing concerns.
FDA GLP-1 safety update in 2026
What did FDA change about suicidal-thought warnings in 2026?
In January 2026, FDA said its review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medicines. It requested removal of that warning from the labeling that still carried it for Saxenda®, Wegovy and Zepbound.
That update matters because old articles may repeat a superseded label warning. It does not mean new or worsening mental-health symptoms should be ignored. Anyone in immediate danger or considering self-harm needs urgent crisis or emergency support regardless of medication use.
Safety pages must be date-stamped and checked against current labeling. A copied list can become inaccurate when FDA revises warnings, indications or precautions.
Compounded GLP-1 medicines and the pre-treatment review
Do compounded GLP-1 medicines carry a brand label?
No. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they reach patients. The Wegovy or Zepbound label cannot be presented as the label for a compounded semaglutide or tirzepatide. Compounded medications are not generic versions of, and have not been shown to be equivalent to, any FDA-approved drug.
FDA has reported adverse events linked to unapproved GLP-1 products marketed for weight loss, including measurement mistakes and use beyond approved schedules. It has also raised concerns about certain salt forms. Products sold outside a licensed pharmacy channel add another layer of risk.
Through Atlas HRT, an independent Florida-licensed physician decides whether Zepbound, Wegovy or a compounded semaglutide or tirzepatide fits, and a licensed partner pharmacy dispenses any prescription. Each route has its own safety page: Zepbound®, Wegovy® and compounded GLP-1 medications.
How should side effects be reviewed before treatment?
A clinician reviews the exact medicine, labeled indication, medical history and current prescriptions. Relevant topics can include prior pancreatitis or gallbladder disease, kidney health, diabetes medicines, severe gastrointestinal disease, diabetic retinopathy, allergy history, planned procedures, pregnancy and the boxed-warning contraindications.
Pregnancy requires special attention because weight loss offers no benefit during pregnancy and product labels direct discontinuation when pregnancy is recognized. Reproductive plans should be discussed before treatment rather than after a positive test.
BMI and clinical screening are covered in the guide to who may qualify for GLP-1 weight management. Neither that guide nor a side-effect list decides whether a particular medicine is appropriate. The physician does.
We think the way a GLP-1 is started matters almost as much as which one is chosen. Rushing the dose to get faster results is the most common path to nausea and quitting early. Slow, steady increases usually win.
Common questions
Are nausea and vomiting expected for everyone?
No. They are common adverse reactions in product trials, but not every patient experiences them and severity varies. Persistent symptoms or difficulty maintaining fluids should be discussed with the clinical team.
Do GLP-1 medicines cause thyroid cancer in humans?
The boxed warnings state that thyroid C-cell tumors occurred in rodents and that human relevance is unknown. The products are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Can GLP-1 therapy cause hair loss?
Hair loss is listed for some weight-management products. Weight change, nutrition, illness and other hair-loss conditions can contribute, so timing and pattern need evaluation.
Atlas HRT Team
Reviewed by · Last reviewed September 2026Atlas HRT specializes in GLP-1 weight loss treatment, including side-effect follow-up, for adults in Florida.
Sources
- Wegovy prescribing information, U.S. Food and Drug Administration
- Zepbound prescribing information, U.S. Food and Drug Administration
- FDA requests removal of suicidal-behavior and ideation warnings, January 13, 2026, U.S. Food and Drug Administration; accessed October 10, 2026
- FDA concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration
- FDA compounding questions and answers, U.S. Food and Drug Administration
